Protection against Toxoplasma gondii brain cyst formation in mice immunized with Toxoplasma gondii cytoskeleton proteins and Lactobacillus casei as adjuvant.
The aim of the study was to evaluate the protection generated in mice against Toxoplasma gondii brain cyst burden by vaccination with T. gondii cytoskeleton proteins using Lactobacillus casei as adjuvant. One hundred and sixty-eight NIH mice were randomly allocated into eight groups of 21 mice each. Animals were immunized as follows: in group 1 with Toxoplasma lysate antigen (TLA) in Freund's modified adjuvant, containing L. casei (FMA), in group 2 with Toxoplasma cytoskeleton proteins (TCPs) in FMA, in group 3 with FMA, in group 4 with phosphate buffered saline (PBS), in group 5 with L. casei dead by heath (Lc), in group 6 with Freund's complete adjuvant (FCA), in group 7 with TLA in FCA, and in group 8 with TCP in FCA. Mean brain cyst burden (+/-S.E.M.) was assessed in mice 8 weeks after challenge with T. gondii Me49 strain (20 cysts per mouse). The percentages of reduction in cyst burden per brain (P<0.01) as compared with the group 4 (control: mean 3181+/-97.5) were 77.25% (724+/-98) in group 1, 88.02% (381+/-97.5) in group 2, 38.92% (1943+/-130.3) in group 3, 44.31% (1771.4+/-102) in group 5, 59.28% (1295.2+/-99.1) in group 7 and 55.69% (1409.5+/-89.9) in group 8. In order of importance, the best protection was obtained in groups 2, 1, 7, 8, 5 and 3. Noticeably the mice inoculated with L. casei alone showed a significant reduction in T. gondii brain cysts (P<0.01), while those animals treated with FCA alone did not. Additionally, IgM anti-T. gondii antibody levels, as determined by ELISA 2 weeks after challenge, were highest in group 2 (P<0.01) than in the other seven groups. Results suggest that T. gondii cytoskeleton proteins with L. casei as adjuvant constitute a good anti-toxoplasmosis vaccine candidate.
Martínez-Gómez
Federico
F
Departamento de Parasitología ENCB-IPN, Mexico.
García-González
Luis Francisco
LF
Mondragón-Flores
Ricardo
R
Bautista-Garfias
Carlos Ramón
CR
D000276:Adjuvants, Immunologic; D000818:Animals; D000913:Antibodies, Protozoan / Q000096:biosynthesis / Q000097:blood; D001921:Brain / Q000469:parasitology; D003598:Cytoskeletal Proteins / Q000276:immunology*; D005260:Female; D007075:Immunoglobulin M / Q000096:biosynthesis / Q000097:blood; D007780:Lacticaseibacillus casei / Q000276:immunology*; D051379:Mice; D015800:Protozoan Proteins / Q000276:immunology*; D016052:Protozoan Vaccines / Q000276:immunology*; D011897:Random Allocation; D014122:Toxoplasma; D014124:Toxoplasmosis, Animal / Q000517:prevention & control*; D016781:Toxoplasmosis, Cerebral / Q000517:prevention & control / Q000662:veterinary*
D000276:Adjuvants, Immunologic; D000913:Antibodies, Protozoan; D003598:Cytoskeletal Proteins; D007075:Immunoglobulin M; D015800:Protozoan Proteins; D016052:Protozoan Vaccines